The use of proprietary vaccine constructs to prime naive CD8+ T-cells via skin dendritic cells and thus enable induction of targeted cellular immunity, establishing tissue-resident CD8+ T-memory cells, is a new vaccination strategy being explored at Emergex Vaccines. Here, Professor Thomas Rademacher, Emeritus Professor of Molecular Medicine – UCL and…
List view / Grid view
Northwestern Medicine scientists have identified a drug, abemaciclib, that inhibits growth of the most aggressive meningiomas and identified a way to predict recurrence more accurately.
Evonetix has been granted a European patent for its silicon chips that leverage semiconductor technology to thermally control DNA synthesis.
BioNTech expands clinical oncology portfolio with first patient dosed in Phase II trial of mRNA-based vaccine for colorectal cancer.
Lynparza with abiraterone is the first PARP inhibitor to demonstrate clinical benefit in combination with a hormonal agent in this setting.
ProQR and Lilly announced a collaboration to combat genetic disorders in the liver and nervous system using Axiomer® RNA editing platform.
CPI have launched an RNA Centre of Excellence in Darlington to boost development, scale-up and manufacture of RNA therapies and vaccines.
Zydus’ ZyCoV-D received emergency use authorisation (EUA) in India, becoming the world’s first plasmid DNA vaccine for COVID-19.
A new US study demonstrated that comprehensive genomic sequencing is crucial for the development of precision medicine for cancer patients.
Researchers have developed a novel gene therapy that could help treat children with incurable genetic and neurodegenerative diseases.
The spin-out from the Universities of Helsinki and Eastern Finland will leverage years of research to test and bring to market a nasal spray vaccine against COVID-19.
The first trial participant has been given INO-4500 in Ghana - INO-4500 is a DNA vaccine candidate being developed to protect against Lassa fever.
Collaborators on Grand Challenge 3 will utilise their combined expertise to transform the oligonucleotide supply chain.
Application note: Synthesis confirmation for nucleic acid medicines – rapid sequence confirmation using a MALDI-TOF mass spectrometer
Medicines that utilise nucleic acids, such as DNA and RNA which control genetic information, are called "nucleic acid medicines".
In this article Pramod Kumar, a Senior Research Analyst (Healthcare) at P&S Intelligence, explores how single-cell analysis techniques are used for both pharmaceutical R&D and clinical, diagnostic applications.